HRP20160485T1 - Anti-mezotelinska protutijela i njihova uporaba - Google Patents
Anti-mezotelinska protutijela i njihova uporaba Download PDFInfo
- Publication number
- HRP20160485T1 HRP20160485T1 HRP20160485TT HRP20160485T HRP20160485T1 HR P20160485 T1 HRP20160485 T1 HR P20160485T1 HR P20160485T T HRP20160485T T HR P20160485TT HR P20160485 T HRP20160485 T HR P20160485T HR P20160485 T1 HRP20160485 T1 HR P20160485T1
- Authority
- HR
- Croatia
- Prior art keywords
- antibody
- seq
- isolated
- fragment
- acid sequence
- Prior art date
Links
- 239000012634 fragment Substances 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 5
- 239000000427 antigen Substances 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 102000003735 Mesothelin Human genes 0.000 claims 3
- 108090000015 Mesothelin Proteins 0.000 claims 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 150000007523 nucleic acids Chemical group 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (12)
1. Izolirano ljudsko protutijelo ili njegov funkcionalni fragment koje sadrži regiju koja veže antigen koji je specifičan za Mezotelin iz SEQ ID NO: 370, naznačeno time da navedeno protutijelo ili njegov funkcionalni fragment prepoznaje epitop za mezotelin koji nije maskiran s karcinom antigenom 125 (CA125), te pri čemu navedeno protutijelo ili njegov funkcionalni fragment internalizira u stanice koje eksprimiraju mezotelin i ima regiju koja veže antigen, pri čemu regija koja veže protutijelo sadrži HCDR 1, HCDR 2, HCDR 3, LCDR 1, LCDR 2 i LCDR 3 pri čemu:
a) HCDR1 je SEQ ID NO: 5,
b) HCDR2 je SEQ ID NO: 39,
c) HCDR3 je SEQ ID NO: 71,
d) LCDR1 je SEQ ID NO: 103,
e) LCDR2 je SEQ ID NO: 133 i
f) LCDR3 je SEQ ID NO: 169.
2. Protutijelo prema zahtjevu 1, naznačeno time da sadrži varijabilnu sekvencu amino kiseline teškog lanca od SEQ ID NO 212
3. Protutijelo prema zahtjevu 1, naznačeno time da sadrži varijabilnu sekvencu amino kiseline lakog lanca od MF-T VL iz Tablice 4.
4. Protutijelo prema bilo kojem od zahtjeva 1 do 3, naznačeno time da je IgG.
5. Izolirani funkcionalni fragment protutijela prema bilo kojem od zahtjeva 1 do 3, naznačeno time da je Fab ili fragment protutijela scFv.
6. Izolirana sekvenca nukleinske kiseline naznačena time da kodira regiju koja veže antigen ljudskog protutijela ili njegov funkcionalni fragment prema bilo kojem od zahtjeva 1 - 5.
7. Vektor naznačen time da sadrži sekvencu nukleinske kiseline prema zahtjevu 6.
8. Izolirana stanica naznačena time da sadrži vektor prema zahtjevu 7.
9. Izolirana stanica prema zahtjevu 9, naznačena time da navedena stanica je bakterijska stanica ili stanica sisavca.
10. Farmaceutski pripravak naznačen time da sadrži protutijelo ili funkcionalni fragment prema bilo kojem od zahtjeva 1-5, te farmaceutski prihvatljiv nosač ili pomoćno sredstvo.
11. Protutijelo ili fragment prema bilo kojem od zahtjeva 1-5 naznačeno time da je za uporabu kao farmaceutski proizvod.
12. Ljudsko protutijelo prema bilo kojem od zahtjeva 1-5, naznačeno time da ljudsko protutijelo je sintetsko ljudsko protutijelo.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US437807P | 2007-11-26 | 2007-11-26 | |
EP08855189.0A EP2215121B1 (en) | 2007-11-26 | 2008-11-19 | Anti-mesothelin antibodies and uses therefor |
PCT/EP2008/009756 WO2009068204A1 (en) | 2007-11-26 | 2008-11-19 | Anti-mesothelin antibodies and uses therefor |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20160485T1 true HRP20160485T1 (hr) | 2016-06-03 |
Family
ID=40351874
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20160485TT HRP20160485T1 (hr) | 2007-11-26 | 2016-05-06 | Anti-mezotelinska protutijela i njihova uporaba |
Country Status (31)
Country | Link |
---|---|
US (3) | US9023351B2 (hr) |
EP (3) | EP3103814A1 (hr) |
JP (3) | JP5608091B2 (hr) |
KR (1) | KR101559599B1 (hr) |
CN (2) | CN101952319B (hr) |
AU (1) | AU2008329221B2 (hr) |
BR (1) | BRPI0819909B8 (hr) |
CA (1) | CA2706529C (hr) |
CO (1) | CO6280409A2 (hr) |
CR (1) | CR11456A (hr) |
CU (1) | CU23833A3 (hr) |
CY (1) | CY1117437T1 (hr) |
DK (1) | DK2215121T3 (hr) |
DO (1) | DOP2010000150A (hr) |
EC (1) | ECSP10010191A (hr) |
ES (1) | ES2569513T3 (hr) |
GT (1) | GT201000148A (hr) |
HK (2) | HK1148541A1 (hr) |
HN (1) | HN2010001062A (hr) |
HR (1) | HRP20160485T1 (hr) |
HU (1) | HUE027358T2 (hr) |
IL (1) | IL205681A0 (hr) |
MA (1) | MA31862B1 (hr) |
MX (1) | MX2010005603A (hr) |
MY (1) | MY157164A (hr) |
NZ (1) | NZ585551A (hr) |
PL (1) | PL2215121T3 (hr) |
SI (1) | SI2215121T1 (hr) |
TN (1) | TN2010000234A1 (hr) |
UA (1) | UA106036C2 (hr) |
WO (1) | WO2009068204A1 (hr) |
Families Citing this family (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009045957A1 (en) * | 2007-10-01 | 2009-04-09 | Medarex, Inc. | Human antibodies that bind mesothelin, and uses thereof |
WO2009068204A1 (en) * | 2007-11-26 | 2009-06-04 | Bayer Schering Pharma Aktiengesellschaft | Anti-mesothelin antibodies and uses therefor |
UY32560A (es) * | 2009-04-29 | 2010-11-30 | Bayer Schering Pharma Ag | Inmunoconjugados de antimesotelina y usos de los mismos |
US8911732B2 (en) * | 2010-12-20 | 2014-12-16 | Genentech, Inc. | Anti-mesothelin antibodies and immunoconjugates |
CN110038135B (zh) | 2011-03-17 | 2021-03-05 | 伯明翰大学 | 重新定向的免疫治疗 |
US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
WO2012143497A2 (de) | 2011-04-21 | 2012-10-26 | Bayer Intellectual Property Gmbh | Neue binder-wirkstoff konjugate (adcs) und ihre verwendung |
US20140004121A1 (en) | 2012-06-27 | 2014-01-02 | Amgen Inc. | Anti-mesothelin binding proteins |
EP2900695B1 (en) * | 2012-09-27 | 2018-01-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Mesothelin antibodies and methods for eliciting potent antitumor activity |
CN103819559B (zh) * | 2013-12-10 | 2016-02-24 | 中国科学院武汉病毒研究所 | 一种抗间皮素纳米抗体及其编码基因和该纳米抗体的用途 |
ES2815098T3 (es) | 2013-12-23 | 2021-03-29 | Bayer Pharma AG | Conjugados de ligadores (ADCs) con inhibidores de KSP |
BR112017006598A2 (pt) * | 2014-09-30 | 2018-04-17 | Neurimmune Holding Ag | anticorpo de repetições antidipeptídeo derivado de ser humano (dprs) |
WO2016126608A1 (en) | 2015-02-02 | 2016-08-11 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
CA2986254A1 (en) | 2015-05-18 | 2016-11-24 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
PE20180610A1 (es) | 2015-06-22 | 2018-04-09 | Bayer Pharma AG | CONJUGADOS DE LIGADOR-PRINCIPIO ACTIVO (ADCs) Y CONJUGADOS DE LIGADOR-PROFARMACO (APDCs) CON GRUPOS ENZIMATICAMENTE ESCINDIBLES |
EP3316908A4 (en) * | 2015-06-30 | 2019-03-06 | Henlius Biotech Co., Ltd. | VASCULAR ENDOTHELIAL GROWTH FACTOR ANTI-RECEPTOR 2 (VEGFR2) ANTIBODY |
AU2016312015A1 (en) * | 2015-08-21 | 2018-04-12 | Crage Medical Co., Limited | Fully human anti-mesothelin antibodies and immune effector cells targeting mesothelin |
KR101782487B1 (ko) * | 2015-09-24 | 2017-09-27 | 재단법인 목암생명과학연구소 | 신규 항-메소텔린 항체 및 이를 포함하는 조성물 |
WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
JP7082055B2 (ja) | 2015-12-22 | 2022-06-07 | ノバルティス アーゲー | 抗癌治療における組み合わせ使用のためのメソテリンキメラ抗原受容体(car)およびpd-l1阻害剤に対する抗体 |
CA3009709A1 (en) | 2015-12-30 | 2017-07-06 | Novartis Ag | Immune effector cell therapies with enhanced efficacy |
EP3418304B1 (en) * | 2016-02-15 | 2021-08-04 | Kanagawa Prefectural Hospital Organization | Recognition of membrane type mucin-like protein and clinical application thereof |
CA3016287A1 (en) | 2016-03-04 | 2017-09-08 | Novartis Ag | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore |
EP3432924A1 (en) | 2016-03-23 | 2019-01-30 | Novartis AG | Cell secreted minibodies and uses thereof |
RU2018136778A (ru) | 2016-03-24 | 2020-04-24 | Байер Фарма Акциенгезельшафт | Пролекарства цитотоксических лекарственных средств, содержащие ферментативно расщепляемые группы |
KR20220133318A (ko) | 2016-04-15 | 2022-10-04 | 노파르티스 아게 | 선택적 단백질 발현을 위한 조성물 및 방법 |
JP2019519223A (ja) | 2016-05-27 | 2019-07-11 | アッヴィ・バイオセラピューティクス・インコーポレイテッド | 免疫調節タンパク質及び腫瘍抗原に結合する二重特異性結合タンパク質 |
JP7022707B2 (ja) | 2016-06-15 | 2022-02-18 | バイエル・ファルマ・アクティエンゲゼルシャフト | Ksp阻害剤および抗cd123抗体を含む特異的抗体-薬物-コンジュゲート(adc) |
GB201612520D0 (en) | 2016-07-19 | 2016-08-31 | F-Star Beta Ltd | Binding molecules |
CN110267677A (zh) | 2016-08-01 | 2019-09-20 | 诺华股份有限公司 | 使用与原m2巨噬细胞分子抑制剂组合的嵌合抗原受体治疗癌症 |
CA3032498A1 (en) | 2016-08-02 | 2018-02-08 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
US20190218294A1 (en) | 2016-09-09 | 2019-07-18 | Bristol-Myers Squibb Company | Use of an anti-pd-1 antibody in combination with an anti-mesothelin antibody in cancer treatment |
CN109689686B (zh) | 2016-10-07 | 2020-08-25 | T细胞受体治疗公司 | 使用融合蛋白进行t细胞受体重编程的组合物和方法 |
US11851491B2 (en) | 2016-11-22 | 2023-12-26 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
EP3548515A1 (en) | 2016-12-01 | 2019-10-09 | Regeneron Pharmaceuticals, Inc. | Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging |
RU2761390C2 (ru) | 2016-12-21 | 2021-12-07 | Байер Фарма Акциенгезельшафт | Конъюгаты связующего и активного вещества (adc), имеющие ферментативно расщепляемые группы |
CA3047522A1 (en) | 2016-12-21 | 2018-06-28 | Bayer Pharma Aktiengesellschaft | Specific antibody drug conjugates (adcs) having ksp inhibitors |
WO2018114798A1 (de) | 2016-12-21 | 2018-06-28 | Bayer Aktiengesellschaft | Prodrugs von cytotoxischen wirkstoffen mit enzymatisch spaltbaren gruppen |
EP3574005B1 (en) | 2017-01-26 | 2021-12-15 | Novartis AG | Cd28 compositions and methods for chimeric antigen receptor therapy |
WO2018232020A1 (en) | 2017-06-13 | 2018-12-20 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
JP6339283B1 (ja) | 2017-10-31 | 2018-06-06 | 国立大学法人 岡山大学 | Dna、ポリペプチド、抗メソセリン抗体、腫瘍イメージング剤及び複合体 |
WO2019105835A1 (en) | 2017-11-29 | 2019-06-06 | Bayer Consumer Care Ag | Combinations of copanlisib and anetumab ravtansine |
EP3728316A1 (en) | 2017-12-19 | 2020-10-28 | F-Star Beta Limited | Fc binding fragments comprising a pd-l1 antigen-binding site |
WO2019124468A1 (ja) | 2017-12-24 | 2019-06-27 | ノイルイミューン・バイオテック株式会社 | ヒトメソセリンを特異的に認識する細胞表面分子、il-7、及びccl19を発現する免疫担当細胞 |
WO2019210153A1 (en) | 2018-04-27 | 2019-10-31 | Novartis Ag | Car t cell therapies with enhanced efficacy |
US20210396739A1 (en) | 2018-05-01 | 2021-12-23 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
WO2019227003A1 (en) | 2018-05-25 | 2019-11-28 | Novartis Ag | Combination therapy with chimeric antigen receptor (car) therapies |
EP3802825A1 (en) | 2018-06-08 | 2021-04-14 | Intellia Therapeutics, Inc. | Compositions and methods for immunooncology |
AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
GB201811450D0 (en) | 2018-07-12 | 2018-08-29 | F Star Delta Ltd | Mesothelin and CD137 binding molecules |
GB201811415D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-Mesothelin Anti bodies |
GB201811408D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | CD137 Binding Molecules |
WO2020047501A1 (en) | 2018-08-30 | 2020-03-05 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
US11702482B2 (en) | 2018-12-17 | 2023-07-18 | Revitope Limited | Twin immune cell engager |
KR20210106437A (ko) | 2018-12-20 | 2021-08-30 | 노파르티스 아게 | 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물 |
CA3123519A1 (en) | 2019-02-15 | 2020-08-20 | Novartis Ag | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
MX2021009763A (es) | 2019-02-15 | 2021-09-08 | Novartis Ag | Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina -2,6-diona y usos de los mismos. |
AU2020235263A1 (en) * | 2019-03-14 | 2021-09-02 | Morphosys Ag | Antibodies targeting C5aR |
CA3133155A1 (en) | 2019-03-19 | 2020-09-24 | Fundacio Privada Institut D'investigacio Oncologica De Vall Hebron | Combination therapy for the treatment for cancer |
WO2020234114A1 (en) | 2019-05-21 | 2020-11-26 | Bayer Aktiengesellschaft | A novel stable high concentration formulation for anetumab ravtansine |
WO2021021825A1 (en) * | 2019-07-29 | 2021-02-04 | Fred Hutchinson Cancer Research Center | Methods and compositions for inducing notch signaling in tumor microenvironments |
MX2022007688A (es) | 2019-12-20 | 2022-07-19 | Amgen Inc | Constructos de anticuerpo multiespecificos agonistas de cd40 dirigidos a mesotelina para el tratamiento de tumores solidos. |
JP2023507190A (ja) | 2019-12-20 | 2023-02-21 | ノバルティス アーゲー | 増殖性疾患を治療するための抗TGFβ抗体及びチェックポイント阻害薬の使用 |
CN116096862A (zh) | 2020-06-11 | 2023-05-09 | 诺华股份有限公司 | Zbtb32抑制剂及其用途 |
WO2021260528A1 (en) | 2020-06-23 | 2021-12-30 | Novartis Ag | Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
WO2022029573A1 (en) | 2020-08-03 | 2022-02-10 | Novartis Ag | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途 |
TW202321296A (zh) | 2021-10-06 | 2023-06-01 | 美商鏈接免疫療法公司 | 抗間皮素抗原結合分子及其用途 |
WO2023214325A1 (en) | 2022-05-05 | 2023-11-09 | Novartis Ag | Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors |
WO2024050524A1 (en) | 2022-09-01 | 2024-03-07 | University Of Georgia Research Foundation, Inc. | Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death |
WO2024089013A1 (en) | 2022-10-25 | 2024-05-02 | Peptomyc, S.L. | Combination therapy for the treatment of cancer |
WO2024102954A1 (en) | 2022-11-10 | 2024-05-16 | Massachusetts Institute Of Technology | Activation induced clipping system (aics) |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4657760A (en) | 1979-03-20 | 1987-04-14 | Ortho Pharmaceutical Corporation | Methods and compositions using monoclonal antibody to human T cells |
US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
US6180377B1 (en) * | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
DE69621940T2 (de) | 1995-08-18 | 2003-01-16 | Morphosys Ag | Protein-/(poly)peptidbibliotheken |
US6083502A (en) | 1996-01-05 | 2000-07-04 | The United States Of America As Represented By The Department Of Health And Human Services | Mesothelium antigen and methods and kits for targeting it |
CA2318576C (en) * | 1997-12-01 | 2009-04-14 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Antibodies, including fv molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use |
US6809184B1 (en) * | 1997-12-01 | 2004-10-26 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Antibodies, including FV molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use |
WO2000050900A2 (en) * | 1999-02-26 | 2000-08-31 | Pacific Northwest Research Institute | Methods and compositions for diagnosing carcinomas |
ES2327382T3 (es) | 1999-07-20 | 2009-10-29 | Morphosys Ag | Metodos para presentar (poli)peptidos/proteinas en particulas de bacteriofagos a traves de enlaces disulfuro. |
JP4949373B2 (ja) | 2005-03-10 | 2012-06-06 | モルフォテック、インク. | 抗メソテリン抗体 |
WO2006124641A2 (en) * | 2005-05-12 | 2006-11-23 | The Government Of The United States, As Represented By The Secretary Of Health And Human Services, National Institutes Of Health | Anti-mesothelin antibodies useful for immunological assays |
DK3620171T3 (da) | 2005-05-18 | 2022-06-07 | Morphosys Ag | Anti-GM-CSF-antistoffer og anvendelser af disse |
JP2008541758A (ja) * | 2005-06-02 | 2008-11-27 | アストラゼネカ エービー | Cd20に対する抗体およびその使用 |
WO2009045957A1 (en) * | 2007-10-01 | 2009-04-09 | Medarex, Inc. | Human antibodies that bind mesothelin, and uses thereof |
WO2009068204A1 (en) * | 2007-11-26 | 2009-06-04 | Bayer Schering Pharma Aktiengesellschaft | Anti-mesothelin antibodies and uses therefor |
-
2008
- 2008-11-19 WO PCT/EP2008/009756 patent/WO2009068204A1/en active Application Filing
- 2008-11-19 CN CN200880125390.8A patent/CN101952319B/zh active Active
- 2008-11-19 NZ NZ585551A patent/NZ585551A/en unknown
- 2008-11-19 BR BRPI0819909A patent/BRPI0819909B8/pt active IP Right Grant
- 2008-11-19 UA UAA201008006A patent/UA106036C2/uk unknown
- 2008-11-19 CN CN201410396441.8A patent/CN104151429B/zh active Active
- 2008-11-19 MX MX2010005603A patent/MX2010005603A/es active IP Right Grant
- 2008-11-19 DK DK08855189.0T patent/DK2215121T3/en active
- 2008-11-19 SI SI200831603A patent/SI2215121T1/sl unknown
- 2008-11-19 EP EP16170412.7A patent/EP3103814A1/en not_active Withdrawn
- 2008-11-19 EP EP08855189.0A patent/EP2215121B1/en active Active
- 2008-11-19 PL PL08855189T patent/PL2215121T3/pl unknown
- 2008-11-19 EP EP13168583.6A patent/EP2634196A1/en not_active Ceased
- 2008-11-19 MY MYPI2010002379A patent/MY157164A/en unknown
- 2008-11-19 US US12/744,849 patent/US9023351B2/en active Active
- 2008-11-19 ES ES08855189.0T patent/ES2569513T3/es active Active
- 2008-11-19 JP JP2010535269A patent/JP5608091B2/ja active Active
- 2008-11-19 KR KR1020107011375A patent/KR101559599B1/ko active IP Right Grant
- 2008-11-19 HU HUE08855189A patent/HUE027358T2/en unknown
- 2008-11-19 AU AU2008329221A patent/AU2008329221B2/en active Active
- 2008-11-19 CA CA2706529A patent/CA2706529C/en active Active
-
2010
- 2010-05-11 IL IL205681A patent/IL205681A0/en active IP Right Grant
- 2010-05-20 GT GT201000148A patent/GT201000148A/es unknown
- 2010-05-20 DO DO2010000150A patent/DOP2010000150A/es unknown
- 2010-05-21 HN HN2010001062A patent/HN2010001062A/es unknown
- 2010-05-21 CR CR11456A patent/CR11456A/es unknown
- 2010-05-21 CO CO10061059A patent/CO6280409A2/es not_active Application Discontinuation
- 2010-05-21 CU CU2010000098A patent/CU23833A3/es active IP Right Grant
- 2010-05-21 EC EC2010010191A patent/ECSP10010191A/es unknown
- 2010-05-24 MA MA32865A patent/MA31862B1/fr unknown
- 2010-05-25 TN TN2010000234A patent/TN2010000234A1/fr unknown
-
2011
- 2011-03-16 HK HK11102654.0A patent/HK1148541A1/xx unknown
-
2014
- 2014-07-03 JP JP2014137893A patent/JP2014221064A/ja active Pending
-
2015
- 2015-02-10 HK HK15101434.5A patent/HK1200856A1/xx unknown
- 2015-03-11 US US14/645,411 patent/US20150259433A1/en not_active Abandoned
-
2016
- 2016-04-27 CY CY20161100353T patent/CY1117437T1/el unknown
- 2016-05-06 HR HRP20160485TT patent/HRP20160485T1/hr unknown
-
2018
- 2018-03-05 US US15/911,748 patent/US20180258181A1/en not_active Abandoned
- 2018-03-05 JP JP2018038254A patent/JP6717869B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20160485T1 (hr) | Anti-mezotelinska protutijela i njihova uporaba | |
HRP20191678T1 (hr) | Pd-1 protutijelo, njegov fragment koji se veže na antigen, i njegova medicinska primjena | |
HRP20151019T1 (hr) | PROTUTIJELA PROTIV c-MET | |
PE20231049A1 (es) | Conjugados de anticuerpo y farmaco basados en eribulina y metodos para su uso | |
NZ609619A (en) | Novel egfr-binding molecules and immunoconjugates thereof | |
HRP20191462T1 (hr) | Antitijela usmjerena protiv her-3 i njihove uporabe | |
JP2016135783A5 (hr) | ||
IL277242B1 (en) | Antibodies that bind cd39 and uses thereof | |
RS54111B1 (en) | ANTI-ALPHA 2 INTEGRIN ANTIBODIES AND THEIR USES | |
NZ628943A (en) | Human antibodies to clostridium difficile toxins | |
NZ714313A (en) | Monoclonal antibodies against tissue factor pathway inhibitor (tfpi) | |
RU2018119165A (ru) | Антитело против лиганда 1 запрограммированной гибели клеток (pd-l1), его антигенсвязывающий фрагмент и их медицинское применение | |
RS53157B (en) | SCLEROSTINE ANTIBODIES | |
HRP20201432T1 (hr) | Il-17a sredstvo za vezivanje i njegove uporabe | |
NZ608660A (en) | Anti-cd48 antibodies and uses thereof | |
NZ610294A (en) | Human antibodies to human tnf-like ligand 1a (tl1a) | |
NZ600768A (en) | Human antibodies to human angiopoietin-like protein 4 | |
HRP20150641T1 (hr) | Anti -cd38 humana antitijela i njihove uporabe | |
NZ598391A (en) | Anti-hepcidin antibodies and uses thereof | |
JP2013121353A5 (hr) | ||
NZ729158A (en) | Anti-ctla4 monoclonal antibody or antigen binding fragment thereof, medicinal composition and use | |
RS54685B1 (en) | ANTI-N3pGlu AMILOID BETA PEPTID ANTIBODIES AND THEIR USES | |
PE20090161A1 (es) | Anticuerpos monoclonales anti cxcl13 | |
NZ595011A (en) | Humanised antibodies that bind and inhibit human DKK-1 protein and composition containing antibodies for treating DKK-1 associated diseases | |
HRP20200882T1 (hr) | Vezujuće molekule specifične za asct2 i njihova uporaba |